Cargando…

Venom-based peptide therapy: insights into anti-cancer mechanism

The 5-year relative survival rate of all types of cancer has increased significantly over the past three decades partly due to the targeted therapy. However, still there are many targeted therapy drugs could play a role only in a portion of cancer patients with specific molecular alternation. It is...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Rui, Mahadevappa, Ravikiran, Kwok, Hang Fai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725072/
https://www.ncbi.nlm.nih.gov/pubmed/29246030
http://dx.doi.org/10.18632/oncotarget.21740
_version_ 1783285470609801216
author Ma, Rui
Mahadevappa, Ravikiran
Kwok, Hang Fai
author_facet Ma, Rui
Mahadevappa, Ravikiran
Kwok, Hang Fai
author_sort Ma, Rui
collection PubMed
description The 5-year relative survival rate of all types of cancer has increased significantly over the past three decades partly due to the targeted therapy. However, still there are many targeted therapy drugs could play a role only in a portion of cancer patients with specific molecular alternation. It is necessary to continue to develop new biological agents which could be used alone and/or in combination with current FDA approved drugs to treat complex cancer diseases. Venom-based drugs have been used for hundreds of years in human history. Nevertheless, the venom-origin of the anti-cancer drug do rarely appear in the pharmaceutical market; and this is due to the fact that the mechanism of action for a large number of the venom drug such as venom-based peptide is not clearly understood. In this review, we focus on discussing some identified venom-based peptides and their anti-cancer mechanisms including the blockade of cancer cell proliferation, invasion, angiogenesis, and metastasis (hallmarks of cancer) to fulfill the gap which is hindering their use in cancer therapy. Furthermore, it also highlights the importance of immunotherapy based on venom peptide. Overall, this review provides readers for further understanding the mechanism of venom peptide and elaborates on the need to explore peptide-based therapeutic strategies.
format Online
Article
Text
id pubmed-5725072
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-57250722017-12-14 Venom-based peptide therapy: insights into anti-cancer mechanism Ma, Rui Mahadevappa, Ravikiran Kwok, Hang Fai Oncotarget Review The 5-year relative survival rate of all types of cancer has increased significantly over the past three decades partly due to the targeted therapy. However, still there are many targeted therapy drugs could play a role only in a portion of cancer patients with specific molecular alternation. It is necessary to continue to develop new biological agents which could be used alone and/or in combination with current FDA approved drugs to treat complex cancer diseases. Venom-based drugs have been used for hundreds of years in human history. Nevertheless, the venom-origin of the anti-cancer drug do rarely appear in the pharmaceutical market; and this is due to the fact that the mechanism of action for a large number of the venom drug such as venom-based peptide is not clearly understood. In this review, we focus on discussing some identified venom-based peptides and their anti-cancer mechanisms including the blockade of cancer cell proliferation, invasion, angiogenesis, and metastasis (hallmarks of cancer) to fulfill the gap which is hindering their use in cancer therapy. Furthermore, it also highlights the importance of immunotherapy based on venom peptide. Overall, this review provides readers for further understanding the mechanism of venom peptide and elaborates on the need to explore peptide-based therapeutic strategies. Impact Journals LLC 2017-10-11 /pmc/articles/PMC5725072/ /pubmed/29246030 http://dx.doi.org/10.18632/oncotarget.21740 Text en Copyright: © 2017 Ma et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Ma, Rui
Mahadevappa, Ravikiran
Kwok, Hang Fai
Venom-based peptide therapy: insights into anti-cancer mechanism
title Venom-based peptide therapy: insights into anti-cancer mechanism
title_full Venom-based peptide therapy: insights into anti-cancer mechanism
title_fullStr Venom-based peptide therapy: insights into anti-cancer mechanism
title_full_unstemmed Venom-based peptide therapy: insights into anti-cancer mechanism
title_short Venom-based peptide therapy: insights into anti-cancer mechanism
title_sort venom-based peptide therapy: insights into anti-cancer mechanism
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725072/
https://www.ncbi.nlm.nih.gov/pubmed/29246030
http://dx.doi.org/10.18632/oncotarget.21740
work_keys_str_mv AT marui venombasedpeptidetherapyinsightsintoanticancermechanism
AT mahadevapparavikiran venombasedpeptidetherapyinsightsintoanticancermechanism
AT kwokhangfai venombasedpeptidetherapyinsightsintoanticancermechanism